Want to see GB:SUN full AI Analyst Report?
SUN Stock Chart & Stats
0.45 p
0.00 p(0.00%)
At close: 4:00 PM EST
0.45 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range0.33 p - 0.74 p
Previous CloseN/A
Volume303.78K
Average Volume (3M)179.78K
Market Cap
£4.66M
Enterprise Value4.28M
Total Cash (Recent Filing)£813.00K
Total Debt (Recent Filing)£665.00K
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Sep 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding932,816,160
10 Day Avg. Volume43,249
30 Day Avg. Volume179,777
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.55
Price to Sales (P/S)0.36
P/FCF Ratio8.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageLow debt (debt-to-equity ~0.09 in 2025) and materially reduced total debt improve financial resilience, lower refinancing risk and provide capacity to fund operations, product development or opportunistic investments. Equity erosion from losses tempers the benefit and requires monitoring over the medium term.
Improved Cash Generation In 2025Operating cash flow and free cash flow turned positive in 2025, signaling improved cash conversion and tighter working-capital management. That strengthens near-term liquidity, reduces reliance on external financing and supports internal funding for maintenance or targeted investments, though absolute cash levels remain modest and have been volatile.
Recurring Consumable Revenue StreamThe business sells single-use consumables alongside reusable instruments; consumables create recurring, procedure-linked revenue and customer stickiness. Structurally this supports revenue resilience and predictability tied to surgical volumes, aiding margin visibility and repeat purchase dynamics versus one-off device sales.
Bears Say
Revenue Softness / Flat-to-down TrendRevenue decreased ~2.6% in 2025 after prior flat/slight declines, indicating weak demand or competitive pressure. Persistent top-line softness limits ability to leverage fixed costs, constrains reinvestment capacity and makes margin recovery harder absent new product adoption, expanded distribution, or market share gains.
Ongoing Net Losses And Negative Operating ProfitThe company remains loss-making (2025 net loss ~-7.7% margin) and recorded negative operating profit, showing it has not returned to sustained profitability since 2022. Continued losses erode shareholder equity, limit reinvestment and strategic flexibility, and increase dependence on cash flow improvements to sustain operations.
Gross Margin DeteriorationGross margins have trended down versus 2022–2023, suggesting structural pricing pressure or rising input costs in core product lines. Persistent margin erosion reduces operating leverage and free cash flow potential, meaning profitability recovery will require either regained pricing power, meaningful cost reductions, or stronger volume growth.
Surgical Innovations News
SUN FAQ
What was Surgical Innovations’s price range in the past 12 months?
Surgical Innovations lowest share price was 0.33 p and its highest was 0.74 p in the past 12 months.
What is Surgical Innovations’s market cap?
Surgical Innovations’s market cap is £4.66M.
When is Surgical Innovations’s upcoming earnings report date?
Surgical Innovations’s upcoming earnings report date is Sep 23, 2026 which is in 80 days.
How were Surgical Innovations’s earnings last quarter?
Surgical Innovations released its earnings results on Apr 21, 2026. The company reported -0.001 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.001 p.
Is Surgical Innovations overvalued?
According to Wall Street analysts Surgical Innovations’s price is currently Overvalued.
Does Surgical Innovations pay dividends?
Surgical Innovations does not currently pay dividends.
What is Surgical Innovations’s EPS estimate?
Surgical Innovations’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Surgical Innovations have?
Surgical Innovations has 932,816,160 shares outstanding.
What happened to Surgical Innovations’s price movement after its last earnings report?
Surgical Innovations reported an EPS of -0.001 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Surgical Innovations?
Currently, no hedge funds are holding shares in GB:SUN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Surgical Innovations
Established in 1988 and headquartered in Leeds, United Kingdom, Surgical Innovations Group plc is an international enterprise engaged in the design, development, manufacturing, and marketing of devices for minimally invasive surgery (SI) and precision engineering applications. Its global presence extends across the UK, Europe, the Asia Pacific region, and the United States. The company operates through three distinct divisions: SI Brand, Original Equipment Manufacturer (OEM), and Distribution. The SI Brand segment is responsible for the research, development, production, and commercialization of its proprietary SI-branded minimally invasive instruments. Key products within this portfolio include the YelloPort Elite and YelloPort +plus laparoscopic port access systems, LogiRange resposable laparoscopic instrument systems, FastClamp laparoscopic clamping systems, and QuickRange single-use laparoscopic instrumentation. The OEM division focuses on crafting and supplying minimally invasive devices for third-party medical device firms, often under their own brand or through co-branding arrangements. This segment also provides comprehensive design and development solutions for creating final medical devices and is involved in the research, development, manufacturing, and sale of minimally invasive technology tailored for precision engineering. Lastly, the Distribution segment handles the supply of various medical products, primarily via its subsidiary, Elemental Healthcare Ltd, and also designs and produces autologous blood products. Surgical Innovations Group plc sells its offerings through a network of independent healthcare distributors, while its own-label products are also distributed through its OEM collaborations.
Technical Analysis
Advanced Medical Solutions
―
Creo Medical
―
―
Smith & Nephew
―
TruSpine Technologies Plc
―